NS与NX方案治疗晚期乳腺癌的疗效及不良反应临床观察

Efficacy and adverse reaction of NS and NX programme in the treatment of metastatic breast cancer

目的:探讨长春瑞滨联合替吉奥胶囊(NS)与联合卡培他滨(NX)治疗晚期乳腺癌(MBC)的疗效及安全性。方法:收治晚期乳腺癌患者60例,随机分为对照组和治疗组。治疗组采用长春瑞滨联合替吉奥胶囊治疗,对照组采用长春瑞滨联合希罗达治疗,比较两组治疗效果。结果:NVB联合S-1的疗效不劣于NVB联合希罗达,且不良反应可控,尤其手足综合征毒性方面,NVB联合S-1方案明显优于NX方案,可提高患者耐受性。结论:NS疗效与NX相当,不良反应轻,可作为晚期乳腺癌的解救方案。

Objective:To explore the efficacy and safety of vinorelbine combined with S-1capsules(NS)and combined withcapecitabine in the treatment of metastatic breast cancer(MBC).Methods:60patients with metastatic breast cancer were selected.They were randomly divided into the control group and the treatment group.The treatment group was treated with vinorelbinecombined with S-1capsules.The control group was treated with vinorelbine combined with capecitabine.We compared thetreatment effect of two groups.Results:The efficacy of NVB combined with S-1was not inferior to NVB combined withcapecitabine,and the adverse reaction was controllable,especially in the hand foot syndrome.NVB combined with S-1scheme wasobviously better than NX scheme.It can improve patient tolerance.Conclusion:The efficacy of NS was comparable to that of NX,and the adverse reactions were mild,which can be used as a salvage regimen for metastatic breast cancer.